CORT (Corcept Therapeutics Incorporated) Stock Financials & Earnings | Market Cap Arena

CORT (Corcept Therapeutics Incorporated) Stock Financials & Earnings | Market Cap Arena

CORTCorcept Therapeutics Incorporated

Mkt Cap$4B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$761M

Net Income (TTM)$99M

EPS (TTM)$0.82

Free Cash Flow (TTM)$142M

Gross Margin98.3%

Op. Margin5.9%

Net Margin13.0%

FCF Margin18.6%

P/S Ratio (TTM)4.7x

P/E Ratio (TTM)35.8x

YoY Rev Growth+12.8%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$106M	$104M	$15M
Q2 23	$118M	$116M	$30M
Q3 23	$124M	$122M	$31M
Q4 23	$135M	$134M	$32M
Q1 24	$147M	$144M	$30M
Q2 24	$164M	$161M	$36M
Q3 24	$183M	$180M	$47M
Q4 24	$182M	$179M	$25M
Q1 25	$157M	$155M	$3M
Q2 25	$194M	$191M	$27M
Q3 25	$208M	$203M	$10M
Q4 25	$202M	$200M	$4M

Revenue Breakdown

Valuation

Quarter	P/S	P/E
Q1 23	8.6x	37.6x
Q2 23	8.3x	37.5x
Q3 23	7.9x	38.8x
Q4 23	7.4x	33.4x
Q1 24	6.8x	30.1x
Q2 24	6.2x	28.2x
Q3 24	5.6x	25.1x
Q4 24	5.3x	25.3x
Q1 25	5.2x	26.7x
Q2 25	5.0x	26.8x
Q3 25	4.8x	33.7x
Q4 25	4.7x	35.8x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	$26M	$26M
Q2 23	$42M	$42M
Q3 23	$53M	$53M
Q4 23	$6M	$6M
Q1 24	$24M	$24M
Q2 24	$41M	$41M
Q3 24	$74M	$72M
Q4 24	$59M	$59M
Q1 25	$5M	$5M
Q2 25	$44M	$44M
Q3 25	$54M	$54M
Q4 25	$38M	$38M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$0
Q2 23	$102K
Q3 23	$37K
Q4 23	$0
Q1 24	$0
Q2 24	$416K
Q3 24	$2M
Q4 24	$121K
Q1 25	$104K
Q2 25	$57K
Q3 25	$0
Q4 25	$50K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+12.8%	+35.7%
Q2 23	+13.9%	+22.5%
Q3 23	+21.5%	+32.4%
Q4 23	+31.4%	+28.8%
Q1 24	+39.0%	+29.2%
Q2 24	+39.1%	+45.5%
Q3 24	+47.7%	+47.1%
Q4 24	+34.3%	+51.0%
Q1 25	+7.1%	+31.1%
Q2 25	+18.7%	+30.9%
Q3 25	+13.7%	+45.2%
Q4 25	+11.1%	+26.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$11M	10.5%
Q2 23	$12M	10.1%
Q3 23	$13M	10.4%
Q4 23	$13M	9.6%
Q1 24	$13M	9.0%
Q2 24	$0	0.0%
Q3 24	$0	0.0%
Q4 24	$17M	9.2%
Q1 25	$22M	13.9%
Q2 25	$19M	9.8%
Q3 25	$0	0.0%
Q4 25	-$64M	-31.5%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 23	$41M	$49M
Q2 23	$43M	$43M
Q3 23	$46M	$45M
Q4 23	$55M	$47M
Q1 24	$59M	$56M
Q2 24	$59M	$67M
Q3 24	$59M	$74M
Q4 24	$70M	$83M
Q1 25	$61M	$91M
Q2 25	$60M	$104M
Q3 25	$69M	$124M
Q4 25	$65M	$130M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$300M	$165M	$465M
Q2 23	$172M	$191M	$363M
Q3 23	$112M	$243M	$355M
Q4 23	$136M	$233M	$368M
Q1 24	$150M	$261M	$411M
Q2 24	$129M	$345M	$473M
Q3 24	$137M	$243M	$380M
Q4 24	$128M	$256M	$383M
Q1 25	$90M	$233M	$323M
Q2 25	$103M	$239M	$342M
Q3 25	$125M	$297M	$422M
Q4 25	$120M	$252M	$372M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	115M	-0.8%
Q2 23	110M	-5.1%
Q3 23	111M	+1.4%
Q4 23	111M	-0.2%
Q1 24	110M	-0.9%
Q2 24	111M	+1.2%
Q3 24	114M	+2.2%
Q4 24	118M	+4.2%
Q1 25	120M	+1.1%
Q2 25	120M	+0.6%
Q3 25	119M	-0.9%
Q4 25	120M	+0.3%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$531K	50
FY 15	$645K	78
FY 16	$790K	103
FY 17	$1M	136
FY 18	$2M	166
FY 19	$1M	206
FY 20	$1M	236
FY 21	$2M	238
FY 22	$1M	299
FY 23	$1M	352
FY 24	$1M	500
FY 25	$1M	730